Evidence map›Paper›PMID 36851527›Full record

ArticleViruses2023

Immunogenicity of Wild Type and Mutant Hepatitis B Surface Antigen Virus-like Particles (VLPs) in Mice with Pre-Existing Immunity against the Wild Type Vector.

Natalie J Kingston, Renae Walsh, Rachel Hammond, Carina C D Joe, George Lovrecz, Stephen Locarnini, Hans J Netter

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Viruses, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Natalie J KingstonInfection and Immunity Program, Monash Biomedicine Discovery Institute, Department of Microbiology, Monash University, Clayton, VIC 3800, Australia.ORCID 0000-0001-7109-6757
Renae WalshVictorian Infectious Diseases Reference Laboratory (VIDRL), Melbourne Health, The Peter Doherty Institute, Melbourne, VIC 3000, Australia.
Rachel HammondVictorian Infectious Diseases Reference Laboratory (VIDRL), Melbourne Health, The Peter Doherty Institute, Melbourne, VIC 3000, Australia.
Carina C D JoeSchool of Science, Royal Melbourne Institute of Technology (RMIT) University, Melbourne, VIC 3001, Australia.ORCID 0000-0003-1304-8727
George LovreczCommonwealth Scientific and Industrial Research Organisation, Clayton, VIC 3169, Australia.
Stephen LocarniniVictorian Infectious Diseases Reference Laboratory (VIDRL), Melbourne Health, The Peter Doherty Institute, Melbourne, VIC 3000, Australia.
Hans J NetterVictorian Infectious Diseases Reference Laboratory (VIDRL), Melbourne Health, The Peter Doherty Institute, Melbourne, VIC 3000, Australia.ORCID 0000-0002-2808-3923
Victorian Infectious Diseases Reference Laboratory · AUCommonwealth Scientific and Industrial Research Organisation · AUUniversity of Leeds · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Virus-like particles (VLPs), composed of the small hepatitis B virus surface antigen (HBsAgS), are the antigenic components of the hepatitis B virus (HBV) vaccine and represent the backbones for a chimeric anti-malaria vaccine and various vaccine candidates. Biological vectors have to face pre-existing anti-vector immune responses due to previous immune exposure. Vector recognition after natural infections or vaccinations can result in unwarranted outcomes, with compromising effects on clinical outcomes. In order to evaluate the impact of a pre-existing anti-HBsAgS immune response, we developed mutant VLPs composed of subunits with reduced HBsAgS-specific antigenicity. The insertion of a

Indexed as

Hepatitis B Surface AntigensImmunogenicity, VaccineMalaria VaccinesPlasmodium falciparumVaccines, Virus-Like ParticleAnimalsEpitopesMalariaMiceMice, Inbred BALB CModels, AnimalProtozoan ProteinsVaccinationcircumsporozoite protein, ProtozoanEpitopesHepatitis B Surface AntigensMalaria VaccinesProtozoan ProteinsVaccines, Virus-Like Particledelivery platformshepatitis B surface antigen (HBsAg)immune sensitizationvectored vaccines

Identifiers

PMID36851527
PMCPMC9963944
OpenAlexW4317733962

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.